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We aimed to characterize the diﬀerent subgroups of ketosis-prone diabetes (KPD) in a sample of Tunisian patients using the
Aβ scheme based on the presence or absence of β-cell autoantibodies (A+ or A−)a n dβ-cell functional reserve (β+o rβ−)a n d
we investigated whether HLA class II alleles could contribute to distinct KPD phenotypes. We enrolled 43 adult patients with
a ﬁrst episode of ketosis. For all patients we evaluated clinical parameters, β-cell autoimmunity, β-cell function and HLA class
II alleles. Frequency distribution of the 4 subgroups was 23.3% A+β−, 23.3% A−β−, 11.6% A+β+ and 41.9% A−β+. Patients
from the group A+β− were signiﬁcantly younger than those from the group A−β− (P = .002). HLA susceptibility markers were
signiﬁcantly more frequent in patients with autoantibodies (P = .003). These patients also had resistance alleles but they were
more frequent in A+β+t h a nA + β− patients (P = .04). Insulin requirement was not associated to the presence or the absence
of HLA susceptibility markers. HLA class II alleles associated with susceptibility to autoimmune diabetes have not allowed us to
further deﬁne Tunisian KPD groups. However, high prevalence of HLA resistance alleles in our patients may reﬂect a particular
genetic background of Tunisian KPD population.
1.Introduction
According to the American Diabetes Association [1], there
are 2 categories of type 1 diabetes, type 1A or immune-
mediated diabetes and type 1B or idiopathic diabetes. The
ﬁrst category is deﬁned by the presence of HLA risk markers
and at least one of these autoantibodies: ICAs (islet cell
antibodies), anti-GAD (glutamate decarboxylase), anti-IA2
(islet antigen 2), and anti-insulin antibodies. Patients from
the second group have neither β-cell autoimmunity markers
nor HLA predisposing alleles.
Diabeticketoacidosishasbeentraditionallyconsideredas
a complication of type 1 diabetes. However, it could occur
in patients with apparently heterogeneous forms of diabetes
[2].Theetiologicalbasesofketosis-pronediabetes(KPD)are
unknown. Several methods of classiﬁcation of these forms
were described [3–6]a n dt h em o s ta c c u r a t ei np r e d i c t i n g
long-term β-cell function and clinical outcome was the Aβ
scheme [7–9]. It is a classiﬁcation based on presence or
absence of auto-immune markers (A+ or A−)a n do fβ-cell
functionalreserve(β+orβ−).Accordingtothisclassiﬁcation
we could distinct 4 groups (A+β+, A−β+, A+β−,a n d
A−β−). This scheme was widely used in American patients
with multiethnic origin, and we were the ﬁrst to use this
scheme to classify North-African patients with KPD [10].
Although this classiﬁcation had high sensitivity and
speciﬁcity to predict long-life insulin requirement for these
patients, evolution could be diﬀerent in the same group.
Genetic factors could contribute to these phenotypic dif-
ferences. In fact, it is widely believed that some HLA class
II alleles are associated with susceptibility or resistance
to autoimmune diabetes in several populations [11, 12].2 Experimental Diabetes Research
Table 1: Demographic and clinicalcharacteristics of the 4 KPD subgroups.
A+β− A+β+A −β+A −β− P
N (%) 10 (23.3) 5 (11.6) 18 (41.8) 10 (23.3) —
Age (years) 36.3 ± 4.9 47 ± 3.8 46.6 ± 10.9 54 ± 1.4 .005
Men-to-women ratio 8/2 3/2 11/7 6/4 ns
Family history of type 1 diabetes (%) 6 (60) 5 (60) 9 (50) 6 (60) ns
BMI (Kg/m2) 24.2 ± 5.2 29.8 ± 4.1 25.5 ± 5.2 25 ± 4n s
C-peptide at baseline (ng/ml) 0.39 ± 0.29 1.42 ± 0.45 1.68 ± 0.76 0.48 ± 0.27 <.0001
C-peptide after stimulation(ng/ml) 0.55 ± 0.31 2.07 ± 1.03 2.10 ± 1.04 0.71 ± 0.35 <.0001
Insulin requirement at 6 months 10 (100) 4 (80) 13 (72.1) 10 (100) ns
ns: non signiﬁcant and BMI: body mass index.
In Tunisia, it has been shown that HLA DRB1∗03,
DRB1∗04, DQB1∗0201, and DQB1∗0302 are risk alleles
for type 1 diabetes, while HLA DRB1∗11, DRB1∗15,
DQB1∗06, and DQB1∗0301 are protective alleles [13, 14].
We aimed in this study to characterize the diﬀerent
subgroups of KPD patients in a sample of Tunisian patients
using the Aβ scheme, and we investigated whether HLA
class II alleles (DR and DQ) associated with susceptibility
or resistance to autoimmune diabetes could contribute to
distinct KPD phenotypes.
2.PatientsandMethods
The protocol was approved by the ethical committee of La
Rabta Hospital (Tunis, Tunisia) and informed consent was
obtained from all participants.
During two years, we recruited all adult patients (>30
years) admitted to the Endocrinology Department of La
Rabta Hospital with a ﬁrst episode of ketosis (without any
history of secondary diabetes, steroid treatment, pregnancy,
or infectious disease). Ketosis onset was deﬁned as the
presence of hyperglycemia (>2g/l), ketonuria (HCO3 <
15mEq/l, pH < 7.30 on arterial blood sample), and imme-
diate need for insulin treatment without previously known
diabetes.
All patients underwent a detailed assessment of medical
history, physical signs, and serum and urine biochemistry.
The weight status was classiﬁed on the basis of body mass
index (BMI). After the resolution of the ketosis episode,
patients were monitored for at least 6 months (maximum 2
years).
ICAs were detected by indirect immunoﬂuorescence
using monkey pancreas section (the Binding Site, UK).
Anti-GAD and anti-IA2 were detected by radio-immuno-
precipitation (Immunotech, France). C-peptide was mea-
sured in serum within one week after ketosis resolution by
radio-immunoprecipitation (Immunotech, France) at initial
presentation and 6 minutes after glucagon stimulation.
Insulin secretion was considered preserved when C-peptide
w a sh i g h e rt h a n1 n g / m la tb a s e l i n eo r1 . 5 n g / m la f t e r
stimulation.
HLA-DRB1 and DQB1 alleles were typed by PCR
sequence-speciﬁcprimer(micro-SSP2L,OneLambda,USA)
according to laboratory procedures.
Statistical analysis was performed using SPSS 11.5. For
means comparison, we used SnedecorF test with Bonferroni
correction where appropriate. Fisher’s exact test was used to
compare allele frequencies. For all statistical tests, P ≤ .05
was considered signiﬁcant.
3.Results
Weenrolledinthisprospectivestudy43patients(25menand
18 women). The mean age was 47 ± 12.1 years.
Fifteen out of these 43 patients (34.8%) had at least one
positive autoantibody, 32 (74.4%) had HLA risk markers of
type 1diabetes, and 23(54.4%)had a correct β-cell function.
According to the Aβ scheme, frequency distribution of
the 4 subgroups was 23.3% A+β−, 23.3% A−β−, 11.6%
A+β+, and 41.8% A−β+. Their demographic and clinical
characteristics are shown in Table 1.P a t i e n t sf r o mt h eg r o u p
A+β− were signiﬁcantly younger than those from the group
A−β− (P = .002). There were no signiﬁcant diﬀerences in
sex, familial history of diabetes, or BMI distribution across
the 4 subgroups.
After six months, all patients of β− groups remained on
insulin treatment. Insulin was successfully discontinued in
26% of patients of β+ groups and all of them remained on
oral agents until the end of the study.
The distribution of HLA susceptibility and resistance
markers to type 1 diabetes in the 4 subgroups is shown
in Figure 1. There is no signiﬁcant diﬀerence among the
HLA susceptibility markers between these four subgroups.
However,HLAsusceptibilitymarkers weresigniﬁcantlymore
frequent in patients with autoantibodies (P = .003). Patients
from A+ subgroups also had resistance alleles but they were
more frequent in A+β+t h a nA + β− patients (80% versus
20%, P = .04).
Compared with the two β− groups, the two groups with
preserved β-cell functional reserve had a higher frequency of
resistance alleles (68.3% versus 40%, P = ns) and the same
frequency of susceptibility alleles (60%).
If we consider every marker alone (Table 2), we found
that the susceptibility allele DQB1∗0201 was signiﬁcantly
more frequent in patients from β− subgroups (P = .03).
Within the β− groups, itsprevalence was signiﬁcantly higher
in A+β− than A−β− patients (P = .02). DQB1∗0201 wasExperimental Diabetes Research 3
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Figure 1: Susceptibility (a) and resistance (b) HLA class II markers in the KPD subgroups. (a) Frequencies of type 1 diabetes susceptibility
alleles were 100%, 100%, 61.1%, and 60% in the A+β−,A + β+, A−β+, and A−β− groups, respectively. (b) Frequencies of type 1 diabetes
resistancealleleswere20%,80%,66.6%,and60%intheA+β−,A+β+,A−β+, andA−β−groups,respectively. ∗ P = .04forA+β−compared
with A+β+g r o u p s .∗∗P = .04 for A+β− compared with A−β− groups.
also found signiﬁcantly more common in patients from A+
subgroups (P = .001).
Concerning resistance alleles, DQB1∗0301 was signiﬁ-
cantly more frequent in patients from β+ subgroups (32.6%
versus 12.5%, P = .02).
In order to better identify the type of diabetes in our
patients we classify them using the Aβ scheme associated
with HLA markers (Table 3). Patients with HLA suscepti-
bility markers were considered as HLA+ and those without
these markers were considered as HLA−.
After six months of followup, insulin was successfully
stopped in only one patient of A+ groups who was
A+β+HLA+; this patient had also resistance alleles. All
A−β− patients remained on insulin treatment. Five out
of 11 patients from A−β+HLA+ patients were under oral
agents and 6/7 of A−β+HLA− patients remained on insulin
treatment.
4.Discussion
In clinical practice, ketosis-onset diabetes in adults is a rare
situation. In fact during two years only 43 patients were
enrolled in this study. Correct classiﬁcation of diabetes type
at the time of diagnosis in such patients is often diﬃcult
but is clearly important in decisions regarding long-term
management. In these patients, recognition of metabolic,
immunological, and genetic markers of type 1 diabetes will
allow patients to remain on insulin therapy because diet and
oral pharmacological therapy are likely to fail [15].
InthisprospectivestudyweusedtheAβschemeandHLA
susceptibilitymarkers to classify our patients presenting with
ﬁrst episode of ketosis.
Proportion of patients who were A+β− was 23.2%.
All of them had HLA susceptibility markers and remained
on insulin treatment after 6 months of followup. These
patients are likely identical with the well-deﬁned form
of autoimmune type 1 diabetes. They were the youngest
patients. Despite being more frequent in childhood patients,
ketosis-onset diabetes in adults has already been reported in
other studies with diﬀerent ethnic origins [5, 16]. We have
already deﬁned this type of patients in a previous study [10].
Recently, using data from the Tunisian National Nutri-
tion Survey, Bouguerra et al. reported that the prevalence of
adult-onset diabetes is increasing [17]. Our study suggests
that autoimmune type 1 diabetes may contribute to the
increasing incidence of diabetes in the Tunisian adult
population.
O n l yﬁ v ep a t i e n t sw e r eA + β+ (11.6%), and there is a
r e a lc o n f u s i o ni nt h el i t e r a t u r econcerning the classiﬁcation
of these patients. According to several European studies,
these patients could be considered as antibody-positive type
2 diabetes or latent autoimmune diabetes of adults (LADA)
[18–20]. Probably the greatest area of confusion involves
the distinction of LADA from type 1 diabetes initially
diagnosed in individuals over the age of 30 years. This form
is characterized by the fact that patients can be initially
managed with diet and oral hypoglycemic agents before
becoming insulin dependent.
It is interesting to note that all A+β+ patients had
HLA susceptibility markers which make the diagnosis of
autoimmune diabetes more plausible. Nevertheless, there is
some support for the view that LADA shares susceptibility
genes with type 1 diabetes [18, 21–23]. On the other hand,
80% ofA+β+ patientsalso had resistance alleles. Coexistence
of susceptibility and resistance alleles was not assessed in
LADA patients in the literature. We cannot explain the exact
role this combination plays in the pathogenesis of diabetes.
In the A+β− and A+β+ groups, we noticed that HLA
susceptibility markers were not useful for the classiﬁcation
of patients, since they were strongly correlated to antibody
production which has already been reported [24, 25].
However, HLA resistance markers were signiﬁcantly higher
in A+β+g r o u p( P = .04). This fact should be investigated
further to see if these genetic factors could contribute to the
delay of β-cell destruction by an immunologic mechanism.
We ﬁnd that the largest group was A−β+ (41.9 %) which
was already reported in other studies [5, 26]. A−β+p a t i e n t s4 Experimental Diabetes Research
Table 2: HLA class II allele frequencies in KPD subgroups.
HLA allele
A+β−
2n = 20
N (%)
A−β−
2n = 20
N (%)
A+β+
2n = 10
N (%)
A−β+
2n = 36
N (%)
Susceptibility
DRB1∗03 6 (30) 3 (15) 2 (20) 6 (16.6)
DRB1∗04 4 (20) 3 (15) 3 (30) 5 (13.8)
DQB1∗0201 12 (60) 4 (20) 3 (30) 6 (16.6)
DQB1∗0302 4 (20) 2 (10) 3 (30) 8 (22.2)
Resistance
DRB1∗11 1 (5) 3 (15) 1 (10) 7 (19.4)
DRB1∗15 2 (10) 2 (10) 0 2 (5.5)
DQB1∗06 1 (5) 3 (15) 0 6 (16.6)
DQB1∗0301 1 (5) 4 (20) 4 (40) 11
(30.5)
Table 3: KPD subgroups according to HLA susceptibility markers.
Autoantibodies A β function Susceptibility HLA Nb %
+ + + 5 11.6
++ − 00
+ − + 10 23.3
+ −− 00
− + + 11 25.6
− + − 7 16.3
−− + 6 13.9
−− − 49 . 3
appear clinically heterogeneous with a wide range of age
and BMI (Table 1). In this group ketosis could be explained
by a functional and partially reversible β-cell deﬁciency in
type 2 diabetes patients secondary to glucotoxicity [27]o r
lipotoxicity [28]. KPD in type 2 diabetes has been ﬁrst
reported in black populations [29, 30] then in other ethnic
groups [5].
After six months of followup, 13/18 (72.2%) of A−β+
patients remained on insulin treatment; this high prevalence
has already been reported by Nalini et al. [31]a f t e r1 2
months of followup.
We noted a high frequency of both autoimmune diabetes
susceptibility and resistance alleles in A−β+ patients. This
was also reported by Nalini et al. [26]i nah e t e r o g e n e o u s
population with multiethnic origin (African American, His-
panic, Caucasian, and Asian KPD A−β+ patients). Among
these patients, African American had the highest prevalence
of autoimmune diabetes susceptibility and resistance alleles.
Although, our population is white African and considered
as Caucasoid, these similarities may be explained by shared
African ancestry.
HLA markers seem to be not useful to distinguish
patients in this heterogeneous group since there was no
association between these markers and insulin requirement
at six months (6/7 of A−β+HLA− patients remained on
insulin treatment, and 5/11 patients from A−β+HLA+
patients were under oral agents).
Other genetic markers were associated with propensity
to KPD [32]. Nevertheless such markers are not suitable for
routine diagnosis.
Among our patients 23.2% were A−β−. β-cell failure
in these patients could have diﬀerent mechanisms including
autoimmune and non-autoimmune ones. Autoimmune β-
cell failure cannot be totally excludedin A−β− patientssince
circulating type 1 diabetes autoantibody levels decline over
time to undetectable levels [33]. This is may be the case for
six of our patients who were A−β−HLA+.
The four A−β−HLA− patients could have either long
evolution type 2 diabetes or type 1B diabetes. This latter
was ﬁrst described in patients of African American origin
[29] then in other ethnic groups (Asian, Native and Hispanic
Americans, or European populations). No study has yet
measured the rate of type 1B diabetes in the Tunisian
population.
Irrespective to HLA alleles, all of the A−β− patients
remained on insulin treatment after six months of followup
suggesting that these markers are not suitable to better
characterize these patients.Experimental Diabetes Research 5
5.Conclusion
Atypical forms of diabetes have sparked a vigorous debate
into the need for reliable markers for classiﬁcation. Despite
the restricted number of our patients, we can conclude
that the Aβ scheme seems to be the strongest indicator
of future metabolic control. HLA class II alleles associated
with susceptibility to autoimmune diabetes have not allowed
us to further deﬁne Tunisian KPD groups. However, high
prevalence of HLA resistance alleles in our patients may
reﬂect a particular genetic background of Tunisian KPD
population. Further studies on a larger cohort are needed
to search the ideal marker to predict the evolution of KPD
patients. Special interest should be given to the implication
of HLA resistance alleles in the physiopathology of this
heterogeneous form of diabetes in association with other
genetic markers.
Acknowledgments
This study was supported by a Grant from the Tunisian
Ministry of health 99/UR/08-74. The authors thank all
subjectswho participated inthis study. There was no conﬂict
of interests.
References
[1] R. Kahn, “Report of the expert committee on the diagnosis
and classiﬁcation of diabetes mellitus,” Diabetes Care, vol. 20,
no. 7, pp. 1183–1197, 1997.
[2] A. Balasubramanyam, R. Nalini, C. S. Hampe, and M.
Maldonado, “Syndromes of ketosis-prone diabetes mellitus,”
Endocrine Reviews, vol. 29, no. 3, pp. 292–302, 2008.
[ 3 ]G .E .U m p i e r r e z ,W .W o o ,W .A .H a g o p i a ne ta l . ,“ I m m u n o -
genetic analysis suggests diﬀerent pathogenesis for obese and
lean African-Americans with diabetic ketoacidosis,” Diabetes
Care, vol. 22, no. 9, pp. 1517–1523, 1999.
[4] A. Pi˜ nero-Pilo˜ na and P. Raskin, “Idiopathic type 1 diabetes,”
Journal of Diabetes and Its Complications, vol. 15, no. 6, pp.
328–335, 2001.
[ 5 ]M .M a l d o n a d o ,C .S .H a m p e ,L .K .G a u re ta l . ,“ K e t o s i s -
prone diabetes: dissection of a heterogeneous syndrome
using an immunogenetic and β-cell functional classiﬁcation,
prospective analysis,andclinicaloutcomes,”Journalof Clinical
Endocrinology and Metabolism, vol. 88, no. 11, pp. 5090–5098,
2003.
[6] F. Mauvais-Jarvis, E. Sobngwi, R. Porcher et al., “Ketosis-
prone type 2 diabetes in patients of sub-Saharan African
origin: clinical pathophysiology and natural history of β-cell
dysfunction andinsulinresistance,”Diabetes,v ol.53,no .3,pp .
645–653, 2004.
[ 7 ]M .M a l d o n a d o ,S .D ’ A m i c o ,M .O t i n i a n o ,A .B a l a s u b r a -
manyam, L. Rodriguez, and E. Cuevas, “Predictors of gly-
caemic control in indigent patients presenting with diabetic
ketoacidosis,” Diabetes, Obesity and Metabolism,v o l .7 ,n o .3 ,
pp. 282–289, 2005.
[8] M. R. Maldonado, M. E. Otiniano, F. Cheema, L. Rodriguez,
and A. Balasubramanyam, “Factors associated with insulin
discontinuation in subjects with ketosis-prone diabetes but
preserved β-cell function,” Diabetic Medicine, vol. 22, no. 12,
pp. 1744–1750, 2005.
[9] A. Balasubramanyam,G. Garza, L. Rodriguez et al., “Accuracy
andpredictive valueofclassiﬁcationschemesforketosis-prone
diabetes,” Diabetes Care, vol. 29, no. 12, pp. 2575–2579, 2006.
[10] F. Harzallah, A. B. Brahim, L. Laadhar et al., “Ketosis-onset
diabetes inTunisianadults:immunologicalmarkersandβ-cell
function,” The Eastern Mediterranean Health Journal, vol. 16,
no. 1, pp. 70–74, 2010.
[11] S. Caillat-Zucman, I. Djilali Saiah, J. Timsit et al., “Insulin
dependent diabetes mellitus (IDDM): 12th International
Histocompatibility Work Shop Study,” in Histocompatibility
Work Shop and Conference, P. Terasaki, Ed., pp. 389–397,
Oxford University Press, 1992.
[12] J. X. She, “Susceptibility to type I diabetes: HLA-DQ and DR
revisited,” Immunology Today, vol. 17, no. 7, pp. 323–329,
1996.
[ 1 3 ]H .A b i dK a m o u n ,S .H m i d a ,H .K a a b ie ta l . ,“ H L Ap o l y m o r -
phism in type 1 diabetes Tunisians,”Annales de G´ en´ etique,v o l .
45, no. 1, pp. 45–50, 2002.
[14] M. Stayoussef, J. Benmansour, A. Q. Al-Irhayim et al.,
“Autoimmune type 1 diabetes genetic susceptibility encoded
b yh u m a nl e u k o c y t ea n t i g e nD R B 1a n dD Q B 1g e n e si n
Tunisia,” Clinical and Vaccine Immunology,v o l .1 6 ,n o .8 ,p p .
1146–1150, 2009.
[15] W. A. Hagopian, C. B. Sanjeevi, I. Kockum et al., “Glutamate
decarboxylase-, insulin-, and islet cell-antibodies and HLA
typing to detect diabetes in a general population-based study
of Swedish children,” Journal of Clinical Investigation, vol. 95,
no. 4, pp. 1505–1511, 1995.
[ 1 6 ]A .G .M o l b a k ,B .C h r i s t a u ,B .M a r n e r ,K .B o r c h - J o h n s e n ,a n d
J. Nerup, “Incidence of insulin-dependent diabetes mellitus in
age groups over 30 years in Denmark,” Diabetic Medicine,v o l .
11, no. 7, pp. 650–655, 1994.
[ 1 7 ]R .B o u g u e r r a ,H .A l b e r t i ,L .B .S a l e me ta l . ,“ T h eg l o b a l
diabetes pandemic:theTunisianexperience,” European Journal
of Clinical Nutrition, vol. 61, no. 2, pp. 160–165, 2007.
[18] T. Tuomi, A. Carlsson, H. Li et al., “Clinical and genetic
characteristics of type 2 diabetes with and without GAD
antibodies,” Diabetes, vol. 48, no. 1, pp. 150–157, 1999.
[19] G. Stenstrom, A. Gotts¨ ater, E. Bakhtadze, B. Berger, and G.
Sundkvist, “Latent autoimmune diabetes in adults: deﬁnition,
prevalence, β-cell function, and treatment,” Diabetes,v o l .5 4 ,
no. 2, pp. S68–S72, 2005.
[ 2 0 ] J .P .P a l m e r ,C .S .H a m p e ,H .C h i u ,A .G o e l ,a n dB .M .B r o o k s -
Worrell, “Is latent autoimmune diabetes in adults distinct
from type 1 diabetes or just type 1 diabetes at an older age?”
Diabetes, vol. 54, no. 2, pp. S62–S67, 2005.
[21] V. Horton, I. Stratton, G. F. Bottazzo et al., “Genetic hetero-
geneity of autoimmune diabetes: age of presentation in adults
is inﬂuenced by HLA DRB1 and DQB1 genotypes (UKPDS
43). UK Prospective Diabetes Study (UKPDS) Group,” Dia-
betologia, vol. 42, no. 5, pp. 608–616, 1999.
[22] M. Desai, E. Zeggini, V. A. Horton et al., “The variable
number of tandem repeats upstream of the insulin gene is a
susceptibility locus for latent autoimmune diabetes in adults,”
Diabetes, vol. 55, no. 6, pp. 1890–1894, 2006.
[23] M. Desai, E. Zeggini, V. A. Horton et al., “An association
analysisoftheHLAgeneregioninlatentautoimmunediabetes
in adults,” Diabetologia, vol. 50, no. 1, pp. 68–73, 2007.
[24] F. Jenhani, R. Bardi, S. Chammakhi, M. Jeddi, and K. Ayed,
“Immunogenetic heterogeneity in type I (insulin-dependent)
diabetes among the Tunisian population. HLA-DR antigens
and organ-speciﬁc autoantibodies (family study),” Journal of
Autoimmunity, vol. 4, no. 3, pp. 553–561, 1991.6 Experimental Diabetes Research
[25] L. Laadhar, A. Gassara, N. Mahfoudh et al., “Susceptibility
markers in Tunisian ﬁrst-degree relatives of patients with type
1d i ab e t e s, ”Annales d’Endocrinologie, vol.68,no.2-3,pp. 181–
185, 2007.
[26] R.Nalini,L.K.Gaur,M.Maldonadoetal.,“HLAclassIIalleles
specify phenotypes of ketosis-prone diabetes,” Diabetes Care,
vol. 31, no. 6, pp. 1195–1200, 2008.
[27] P. Linfoot, C. Bergstrom, and E. Ipp, “Pathophysiology of
ketoacidosis in type 2 diabetes mellitus,” Diabetic Medicine,
vol. 22, no. 10, pp. 1414–1419, 2005.
[28] E. W. Kraegen, G. J. Cooney, J. M. Ye, A. L. Thompson,
and S. M. Furler, “The role of lipids in the pathogenesis
of muscle insulin resistance and beta cell failure in type II
diabetes and obesity,” Experimental and Clinical Endocrinology
and Diabetes, vol. 109, no. 2, pp. S189–S201,2001.
[29] W. E. Winter, N. K. Maclaren, W. J. Riley, D. W. Clarke, M.
S. Kappy, and R. Spillar, “Maturity-onset diabetes of youth in
black Americans,” The New England Journal of Medicine,v o l .
316, no. 6, pp. 285–291, 1987.
[30] E. Sobngwi, F. Mauvais-Jarvis, P. Vexiau, J. C. Mbanya, and J.
F. Gautier, “Diabetes in Africans: part 2: ketosis-proneatypical
diabetes mellitus,” Diabetes and Metabolism,v o l .2 8 ,n o .1 ,p p .
5–12, 2002.
[31] R. Nalini, K. Ozer, M. Maldonado et al., “Presence or absence
of a known diabetic ketoacidosis precipitant deﬁnes distinct
syndromes of ”a-β+” ketosis-prone diabetes based on long-
term β-cell function, human leukocyte antigen class II alleles,
and sex predilection,” Metabolism: Clinical and Experimental,
vol. 59, no. 10, pp. 1448–1455, 2010.
[32] F. Mauvais-Jarvis, S. B. Smith, C. Le May et al., “PAX4
gene variations predispose to ketosis-prone diabetes,” Human
Molecular Genetics,vol. 13, no. 24, pp. 3151–3159, 2004.
[33] C. Pihoker, L. K. Gilliam, C. S. Hampe, and A. Lernmark,
“Autoantibodies in diabetes,” Diabetes, vol. 54, no. 2, pp. S52–
S61, 2005.Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com